Halo Pharma Becomes Independent CDMO After Noramco Sells API Business To Siegfried, Focusing Fully On Drug Product Development And Manufacturing

Halo Pharma, a prominent contract development and manufacturing organization (CDMO) specializing in drug product development and manufacturing, is set to operate as an independent company following the sale of Noramco’s active pharmaceutical ingredient (API) and related businesses to Siegfried.

Halo Pharma became part of the Noramco Group in 2023, after being acquired from Cambrex. With the divestment of the API-focused assets, Halo will now serve as a dedicated platform for drug product CDMO services, allowing the company to focus entirely on developing and manufacturing high-quality pharmaceutical products.

The company’s sterile CDMO operations are expected to be fully operational in the second half of 2026. These operations will feature a state-of-the-art Groninger UFVN FlexFill filling line along with a Skan isolator. The flexible line, which includes interchangeable change parts, is capable of filling vials ranging from 2 to 30 mL, syringes from 0.5 to 10 mL, and cartridges of various sizes, all in ready-to-use formats.

Alongside sterile manufacturing, Halo Pharma will continue to produce oral solids, liquids, and semi-solid products at both of its sites. To support its new sterile capabilities, the company has recently expanded its services to include sterile product development, formulation, and analytical testing, ensuring a comprehensive offering for clients across the pharmaceutical industry.

Lee Karras, CEO of the Noramco Group, stated that focusing on a single area of expertise allows for greater success. He expressed enthusiasm about working closely with the Halo teams at both sites and highlighted that there is already strong interest from established pharmaceutical companies seeking to secure sterile CDMO services in advance.